Home›Trial›NCT06208878
NCT06208878Enrolling by invitation

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

Study Summary

This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies

Conditions
Hematologic MalignancySolid Malignancy
Interventions / Drugs
Non Interventional
View on ClinicalTrials.gov ↗
Sponsor
CRSP
CRISPR Therapeutics
Gene Editing
C54/100
Study Details
Enrollment70 participants
Primary Completion2038-08
Lead SponsorCRISPR Therapeutics AG
Data Retrieved2026-10-14
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Current status: Enrolling by invitation.

Primary completion: 2038-08
Enrolled: 70 participants
Sponsor Catalyst Profile

CRISPR Therapeutics (CRSP) is the sponsoring company for this trial. BiotechSign currently grades this company C (54/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

CRSP Full Pipeline →All Companies →
Other Trials from CRISPR Therapeutics
NCT05643742A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refra…(PHASE1/PHASE2)NCT07491172A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractor…(PHASE1)NCT05565248An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VC…(PHASE1/PHASE2)NCT06925542A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory …(PHASE1)
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.
© 2026 BiotechSign — AI-powered biotech catalyst intelligence